APPLIED NEUROSOLUTIONS.

Applied NeuroSolutions Press Releases
- Applied NeuroSolutions Engages William Blair & Company LLC as its' Strategic Advisor
  - September 8, 2008
- Applied NeuroSolutions' Founding Scientist, Peter Davies, Ph.D., to Receive Lifetime Achievement Award from Alzheimer's Association
  - July 28, 2008
- Applied NeuroSolutions Achieves Q2 2008 Alzheimer's Disease Serum Diagnostic Development Program Milestone
  - July 1, 2008
- Applied NeuroSolutions Q1 2008 Alzheimer's Disease Diagnostic Development Programs Update
  - May 21, 2008
- Applied NeuroSolutions to Offer P-Tau 231 Test for Use in Alzheimer's Disease Clinical Trials
  - May 13, 2008
- Study Shows Applied NeuroSolutions’ Test is a Significant Predictor of the Decline from Mild Cognitive Impairment to Alzheimer’s Disease
  - December 13, 2007
- Applied NeuroSolutions Appoints Ellen R. Hoffing to Additional Role as Chairman of the Board of Directors
  - December 13, 2007
- Applied NeuroSolutions' Founding Scientist, Dr. Peter Davies, to Participate on an Expert Panel on Alzheimer's Disease Hosted by Credit Suisse
  - December 12, 2007
- Applied NeuroSolutions Appoints Healthcare Executive David C. Tiemeier, Ph.D. to Board of Directors
  - October 25, 2007
- Applied NeuroSolutions' Test is the Strongest Predictor of the Decline from Mild Cognitive Impairment to Alzheimer's Disease
  - October 15, 2007
- Applied NeuroSolutions Announces U.S. Patent Issued Covering Unique Gene Potentially Involved in Onset of Alzheimer's Disease
  - October 9, 2007
- Applied NeuroSolutions Raises $2.9 Million in a Private Placement Financing
  - October 2, 2007
- Applied NeuroSolutions’ Founding Scientist, Dr. Peter Davies, to Participate on Panel at Alzheimer’s Association New York City Chapter’s 20th Annual Meeting
  - September 18, 2007
- Applied NeuroSolutions Provides Update on Alzheimer's Disease Therapeutic Collaboration with Eli Lilly and Company
  - August 8, 2007
- Applied NeuroSolutions’ P-Tau 231 Cerebrospinal Fluid Diagnostic Test Identified as a Reliable Biomarker for Alzheimer’s Disease
  - July 25, 2007
- Dr. Peter Davies, Applied NeuroSolutions’ Founding Scientist, to be Featured on a National Public Radio Broadcast Panel on Alzheimer’s - June 13, 2007
- Applied NeuroSolutions Founding Scientist, Dr. Peter Davies, Featured in New York Times Article on Alzheimer’s Disease
  - June 11, 2007
- Applied NeuroSolutions to Discuss Its Therapeutic and Diagnostic Programs in the Multi-Billion Dollar Alzheimer's Field Live on Market News First - May 22, 2007
- Applied NeuroSolutions Hires Top Ranked Analyst, Ryan Rauch, to Direct its Investor Relations Program - March 06, 2007
- US Patent Issued Covering Applied NeuroSolutions’ Mice with Human Tau - January 24, 2007
- Research Firm Upgrades Applied NeuroSolutions’ Rating, Doubles Price Target - November 30, 2006
- Applied NeuroSolutions Announces Agreement with Eli Lilly and Company to Develop Therapeutics to Treat Alzheimer’s Disease - November 28, 2006
- Applied NeuroSolutions Appoints Healthcare Leader Alan L. Heller to Board of Directors - September 07, 2006
- Applied NeuroSolutions Appoints Ellen Hoffing as President and CEO - August 29, 2006
- Applied NeuroSolutions Announces Appointment of Robert S. Vaters as Chairman of The Board of Directors - June 27, 2006
- APPLIED NEUROSOLUTIONS ANNOUNCES 2005 RESULTS - Company Provides Corporate Update - March 23, 2006
- Applied NeuroSolutions’ Founding Scientist Quoted In Investor’s Business Daily (IBD) - January 09, 2006
- Increase in Specific, Abnormal Brain Protein May Predict Onset of Alzheimer’s Disease, Study Shows - January 04, 2006
- Applied NeuroSolutions Renews Agreement with Peter Davies, Ph.D. - December 12, 2005
- Applied NeuroSolutions Retains Financial Dynamics as its Financial Communications and Investor Relations Agency - December 06, 2005
- Applied NeuroSolutions Appoints Inamed Executive Robert S. Vaters to its Board of Directors - October 20, 2005
- Applied NeuroSolutions’ Alzheimer’s Test Expected to be Featured on “Lou Adler’s Medical Journal” Radio Report - October 18, 2005
- Applied NeuroSolutions Takes First Step In Commercialization of Diagnostic Alzheimer’s Disease Test - September 08, 2005
- Applied NeuroSolutions, Inc. President and CEO Interviewed on “Business Talk This Morning” Radio Show - August 31, 2005
- Applied NeuroSolutions Profiled in Chicago Sun-Times - August 08, 2005
- Applied NeuroSolutions' Diagnostic Alzheimer's Disease Test Focus of Story on CBS News TV Stations - August 03, 2005
- Applied NeuroSolutions Adds Jay B. Langner, Board Chairman of Montefiore Medical Center, to its Board of Directors - July 26, 2005
- Applied NeuroSolutions Sees Abnormal Cell Division as Possible Precursor of Alzheimer's Disease- June 20, 2005
- Applied NeuroSolutions Announces Research Program For Novel Approach To Alzheimer's Disease Therapeutics- June 06, 2005
- Applied NeuroSolutions Biomarker May Predict Alzheimer's Disease Progression - May 25, 2005
- Applied NeuroSolutions Ready to Ship First Research Mouse to Exhibit Key Alzheimer's Pathology - April 06, 2005
- Applied NeuroSolutions Receives U.S. Patent on Alzheimer's Blood Test Technology - March 10, 2005
- Johns Hopkins "Memory Bulletin" Comments on Applied NeuroSolutions Alzheimer's Disease Diagnostic - February 28, 2005
- bioMérieux to License Applied NeuroSolutions’ Technology to Diagnose Alzheimer’s Disease - December 13, 2004
- Applied NeuroSolutions’ p-tau 231 Assay Greatly Improves Early Stage Alzheimer’s Disease Detection Journal of Internal Medicine Study Shows - September 30, 2004
- Applied NeuroSolutions Announces Resignation of Chief Executive Officer and Elevation of John F. DeBernardis, Ph.D. to Chief Executive Officer - September 28, 2004
- Dr. Peter Davies Reviews And Questions Conventional Approaches In Alzheimer’s Disease Research - July 21, 2004
- Applied Neurosolutions' (Otc Bb: Apns) Biomarker Improves On Early Diagnosis Of Alzheimer’s Disease - July 20, 2004
- Applied Neurosolutions’ Bio-Marker Determined To Be Useful In Diagnosing Mildly Cognitively Impaired (Mci) Patients – Assay May Detect Early-Stage Alzheimer’s Disease In Patients - July 19, 2004
- Applied Neurosolutions’ Founding Scientist Co-Chairs Alzheimer’s Panel To Examine New Research Models - July 19, 2004
- Applied NeuroSolutions Appoints New Board Member - June 18, 2004
- APNS Announces Delisting of Unauthorized Listing on Berlin-Bremen Stock Exchange - June 2, 2004
- Applied NeuroSolutions Completes $8 Million Private Placement Converts Bridge Loans to Equity - Feb. 12, 2004
- Independent Study Concludes Applied NeuroSolutions’ Alzheimer’s Test Exceeds Industry Goals and Standards - Jan. 26, 2004
- Applied NeuroSolutions’ Founding Scientist Receives Ten Year NIH Award - Dec. 15, 2003
- APNS Discusses Diagnosing Alzheimer's Disease on CEOcast Today - Dec. 10, 2003
- Hemoxymed IS NOW Applied NeuroSolutions, Inc. - Nov. 25, 2003
- Applied NeuroSolutions Signs Agreement with Novartis - Nov. 19, 2003
- Hemoxymed, Inc. To Be Re-Named Applied NeuroSolutions, Inc. - Oct. 14, 2003
- Hemoxymed to Market Unique Animal Model for Alzheimer's Disease - Sept. 16, 2003